NASDAQ: WGSGenedx Holdings Corp Stock
$95.47-2.81 (-2.86%)
Updated Apr 17, 2025
WGS Price
$95.47
Fair Value Price
N/A
Market Cap
$2.68B
52 Week Low
$9.60
52 Week High
$115.60
P/E
-49.21x
P/B
10.93x
P/S
6.77x
PEG
N/A
Dividend Yield
N/A
Revenue
$305.45M
Earnings
-$52.29M
Gross Margin
63.6%
Operating Margin
-16.24%
Profit Margin
-17.1%
Debt to Equity
0.71
Operating Cash Flow
-$28M
Beta
1.74
Next Earnings
Apr 28, 2025
Ex-Dividend
N/A
Next Dividend
N/A
WGS Overview
GeneDx Holdings Corp. is a patient centered health intelligence company. It engages in transforming healthcare by applying AI and machine learning to multidimensional, longitudinal clinical and genomic data to build dynamic models of human health and defining optimal, individualized health trajectories. The firm, through its Centrellis health intelligence platform, generates a more complete understanding of disease and wellness and provides science-driven solutions to the most pressing medical needs. The company was founded by Eric Schadt in October 2015 and is headquartered in Stamford, CT.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine WGS's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Health Information Service
Industry Rating
B
WGS
Ranked#16 of 44
Ranked#16 of 44
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $149.00 | A | |
| $62.37 | A | |
| $1.42 | B |
Be the first to know about important WGS news, forecast changes, insider trades & much more!
WGS News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how WGS scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
WGS is unprofitable, so we are unable to calculate its intrinsic value according to an updated version of Benjamin Graham's Formula from "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
WGS is poor value based on its book value relative to its share price (10.93x), compared to the US Health Information Services industry average (3.39x)
P/B vs Industry Valuation
WGS is unprofitable, so we... subscribe to Premium to read more.
PEG Value Valuation
There are 30 more WGS due diligence checks available for Premium users.
Valuation
WGS fair value
Fair Value of WGS stock based on Discounted Cash Flow (DCF)
Price
$95.47
Fair Value
-$56.72
Undervalued by
268.32%
WGS is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
WGS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-49.21x
Industry
11.14x
Market
27.98x
WGS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
10.93x
Industry
3.39x
WGS is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
WGS's financial health
Profit margin
Revenue
$95.6M
Net Income
$5.4M
Profit Margin
5.7%
WGS's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
WGS's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$419.4M
Liabilities
$174.1M
Debt to equity
0.71
WGS's short-term assets ($197.97M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
WGS's short-term assets ($197.97M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
WGS's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
WGS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$3.2M
Investing
-$519.0k
Financing
$31.0M
WGS's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
WGS vs Health Information Service Stocks
Genedx Holdings Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.